Video

Omar Hussain, DO: How is MACRA Going to Affect Me?

Author(s):

Physicians who do not comply with MACRA will face 4% penalties in 2019.

For most doctors, MACRA, or the Medicare Access and CHIP Reauthorization Act, boils down to new language surrounding old practices. According to Omar Hussain, DO it's language that's important to understand - and quickly.

Hussain:

It's going to affect you in terms of what you have to keep track of on your daily outpatient basis. Most of these measures, for us, are outpatients. So you gotta track what you're doing, and it's usually through your electronic health records.

After you've tracked it, you figure out how you're doing on it has an effect on your bottom line through medicare. It can affect up to negative 4% if you choose to ignore it altogether. In 2019, you'll start getting negative 4% on all the bills you submit. If you submit anything right now - one patient, one measure in 2017, you at least stay neutral for 2019.

Then, if you start right now, starting to record data, collect it, submit it, then there's a chance you can get an increase in your medicare reimbursement for the same work you do right now.

A lot of us have already been in a MACRA-type world with different reporting, with PQRS, with meaningful use, and other quality measures. We're all kinda doing it. I just think MACRA kinda relabels some of it, and rehouses it in one place.

So, while getting to learn the language could be difficult - some of the words have changed - in all, the activity has stayed the same.

My own practice manager, who is doing a lot of help with data collection just came to that realization last week. She was like, "This is what I've been doing already. I'm already doing PQRS for 9 of you, I'm already doing meaningful use for 9 of you."

It's just the same thing, different words, different labels.

Related Videos
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
Eric Lawitz, MD | Credit: UT Health San Antonio
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
A. Sidney Barritt, MD | Credit: UNC School of Medicine
© 2024 MJH Life Sciences

All rights reserved.